首页> 外文会议>ESPE Advanced Seminar in Developmental Endocrinology >Diabetes in Werf Young Children and Mutations in the Insulin-Secreting Cell Potassium Channel Genes: Therapeutic Consequences
【24h】

Diabetes in Werf Young Children and Mutations in the Insulin-Secreting Cell Potassium Channel Genes: Therapeutic Consequences

机译:Werf幼儿糖尿病幼儿和胰岛素分泌细胞钾通道基因的突变:治疗后果

获取原文

摘要

ATP-sensitive potassium (K_(Atp)) channels regulate the flux of K~+ ions across the cell membranes and couple cell metabolism to electrical activity.These channels are octameric complexes of 4 pore-forming Kir and 4 regulatory sulphonylurea receptor (SUR) subunits.The K_(ATP) channels play multiple physiological roles in the glucose metabolism regulation, especially in the pancreatic beta-cells where they regulate insulin secretion, in response to increases in ATP concentration. Several studies have reported activating mutations in the KCNJ11 gene, encoding the Kir6.2 subunit of the pancreatic K_(ATP) channel, in patients with permanent neonatal diabetes mellitus for 30-50% of the cases. These mutations result in reduced ATP sensitivity of the K_(ATP) channels compared with the wild types. The level of channel activity defect is responsible for different clinical features: the 'mild' form confers isolated permanent neonatal diabetes whereas the severe form combines diabetes and neurological symptoms such as epilepsy, developmental delay, muscle weakness and mild dysmorphic features. The very recently elucidated mutations in the ABCC8 gene, encoding the second K_(ATP) channel subunit, SUR1, account for transient neonatal diabetes mellitus as well as permanent neonatal diabetes mellitus cases. In vitro studies showed no attenuation of ATP sensitivity but an increase in the opening probability of the channel through interaction of the mutated SUR1 subunit on Kir6.2. Sulphonylureas close K_(ATP) channels by binding with high affinity to SUR suggesting they could replace insulin in these patients. Subsequently, more than 60 patients have been reported as successfully switched from insulin subcutaneous injections to oral sulphonylurea therapy, with an improvement in their glycated hemoglobin. The transfer from insulin injections to oral gliben-clamide therapy seems highly effective and safe for most patients, and should be performed in accordance with the legal rules for the use of such a drug, specially in children, in each country.
机译:ATP敏感性钾(K_(ATP))通道调节穿过细胞膜和耦合细胞代谢到电activity.These通道K +离子的通量是4孔形成基尔和4监管磺酰脲受体(SUR)的八聚体复合物subunits.The K_(ATP)通道中的葡萄糖代谢调控中发挥多种生理作用,特别是在它们调节胰岛素分泌中,响应于在ATP浓度增加胰腺β细胞。一些研究报告,活化突变的KCNJ11基因,编码胰腺K_(ATP)通道Kir6.2的亚基,患者永久新生儿糖尿病的病例30-50%。这些突变导致与野生型相比,K_(ATP)通道的减少ATP敏感性。通道活性缺陷的水平是负责不同的临床特征:“温和”的形式赋予分离永久新生儿糖尿病而严重形式联合糖尿病和神经症状,如癫痫,发育迟缓,肌肉无力和轻度畸形特征。在ABCC8基因的最近阐明突变,编码第二K_(ATP)通道亚基,SUR1,占瞬态新生儿糖尿病以及永久新生儿糖尿病病例。体外研究表明没有衰减ATP敏感性的,而是通过对Kir6.2的突变SUR1亚单位相互作用的增加通道的开放概率。磺酰脲类关闭K_(ATP)通道通过与高亲和力结合SUR暗示他们可以在这些患者中替换胰岛素。随后,60名多名患者已经被报告为胰岛素皮下注射成功切换到口服磺脲类药物治疗,在他们的糖化血红蛋白的改善。从注射胰岛素口服gliben-clamide治疗转移似乎对大多数患者高效,安全的,并应按照法律规定对使用这种药物,特别是在儿童中进行,在每一个国家。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号